RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results

Bulletin Express

昨天

RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the related public disclosure.

The meeting will be chaired by Mr. Wang Weidong, who serves as chairman and executive director. The current board comprises four executive directors (Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Mr. Lin Jian), two non-executive directors (Dr. Wang Liqiang, Dr. Su Xiaodi), and three independent non-executive directors (Mr. Hao Xianjing, Mr. Chen Yunjin, Mr. Huang Guobin).

The company is incorporated in the People’s Republic of China and remains committed to timely dissemination of its financial performance. Details of the unaudited first-quarter results will be published following board approval.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1174576271"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174576271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174576271?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174576271","market":"hk","top_or_hot":-1,"title":"RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results","media":"Bulletin Express","content":"<p>RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the related public disclosure.</p>\n<p>The meeting will be chaired by Mr. Wang Weidong, who serves as chairman and executive director. The current board comprises four executive directors (Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Mr. Lin Jian), two non-executive directors (Dr. Wang Liqiang, Dr. Su Xiaodi), and three independent non-executive directors (Mr. Hao Xianjing, Mr. Chen Yunjin, Mr. Huang Guobin).</p>\n<p>The company is incorporated in the People’s Republic of China and remains committed to timely dissemination of its financial performance. Details of the unaudited first-quarter results will be published following board approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-04-16 17:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the related public disclosure.</p>\n<p>The meeting will be chaired by Mr. Wang Weidong, who serves as chairman and executive director. The current board comprises four executive directors (Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Mr. Lin Jian), two non-executive directors (Dr. Wang Liqiang, Dr. Su Xiaodi), and three independent non-executive directors (Mr. Hao Xianjing, Mr. Chen Yunjin, Mr. Huang Guobin).</p>\n<p>The company is incorporated in the People’s Republic of China and remains committed to timely dissemination of its financial performance. Details of the unaudited first-quarter results will be published following board approval.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"榮昌生物","start_time":0,"source_url":"","article_id":"1174576271","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174576271","pubTimestamp":1776330231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"RemeGen计划于2026年4月28日召开董事会，审查2026年第一季度未经审计的业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the related public disclosure.\nThe meeting will be chaired by Mr. Wang Weidong, who serves as chairman and executive director. The current board comprises four executive directors (Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Mr. Lin Jian), two non-executive directors (Dr. Wang Liqiang, Dr. Su Xiaodi), and three independent non-executive directors (Mr. Hao Xianjing, Mr. Chen Yunjin, Mr. Huang Guobin).\nThe company is incorporated in the People’s Republic of China and remains committed to timely dissemination of its financial performance. Details of the unaudited first-quarter results will be published following board approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}